Charged Alpha logo
CHARGED ALPHA
Stock Analysis
PEN Healthcare Latest YouTube: Q1 2026 Published 2026-04-23

Penumbra, Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

PEN Stock: EPS Beats by 8% — Q1 2026 Earnings Analysis

Published 2026-04-23

Library coverage

Episodes tracked
2
Episodes linked
2
Latest video
Q1 2026
2026-04-23
Podcast available
Yes
Current price
$325.18
+1.42 (+0.44%)
Trailing / Forward P/E
80.09x
Forward: 53.03x
Market cap / Volume
Volume:
Revenue / Earnings Growth
14.9%
Earnings: -23.5%
Margins
10.5% op
Gross: 67.8% · Net: 10.7%
Balance sheet
5.75x current
Debt / Equity: 13.9
52-week range / Beta
$221.26 - $362.41
Beta: 0.70
Analyst target
$361.83
Upside: 11.3%
Cash / shareholder return
1.26% FCF yield
Dividend yield: —

Company context

Industry: Medical Devices
Country: United States
Employees:
Price to book: 8.37x
Return on equity: 11.4%
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Price chart

Market context for PEN

Competitive view

PEN vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Penumbra, Inc. latest YouTube video thumbnail YouTube
Penumbra, Inc.
PEN
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Intuitive Surgical latest YouTube video thumbnail YouTube
Intuitive Surgical
ISRG
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Johnson & Johnson latest YouTube video thumbnail YouTube
Johnson & Johnson
JNJ
Latest video
Q2 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
PEN
$12.81B
Penumbra, Inc.
ISRG
$135.72B
Intuitive Surgical
JNJ
$651.25B
Johnson & Johnson
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
PEN
80.1x
Penumbra, Inc.
ISRG
43.5x
Intuitive Surgical
JNJ
31.4x
Johnson & Johnson
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
PEN
53.0x
Penumbra, Inc.
ISRG
31.4x
Intuitive Surgical
JNJ
22.0x
Johnson & Johnson
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
PEN
14.9%
Penumbra, Inc.
ISRG
18.5%
Intuitive Surgical
JNJ
6.6%
Johnson & Johnson
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
PEN
-23.5%
Penumbra, Inc.
ISRG
26.5%
Intuitive Surgical
JNJ
-0.9%
Johnson & Johnson
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
PEN
10.5%
Penumbra, Inc.
ISRG
33.6%
Intuitive Surgical
JNJ
29.2%
Johnson & Johnson
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
PEN
67.8%
Penumbra, Inc.
ISRG
66.7%
Intuitive Surgical
JNJ
68.1%
Johnson & Johnson
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
PEN
10.7%
Penumbra, Inc.
ISRG
28.4%
Intuitive Surgical
JNJ
21.5%
Johnson & Johnson
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
PEN
11.4%
Penumbra, Inc.
ISRG
17.4%
Intuitive Surgical
JNJ
25.7%
Johnson & Johnson
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
PEN
1.3%
Penumbra, Inc.
ISRG
1.9%
Intuitive Surgical
JNJ
2.6%
Johnson & Johnson
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
PEN
13.90x
Penumbra, Inc.
ISRG
Intuitive Surgical
JNJ
57.71x
Johnson & Johnson
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
PEN
5.75x
Penumbra, Inc.
ISRG
4.96x
Intuitive Surgical
JNJ
1.09x
Johnson & Johnson
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
PEN
0.70
Penumbra, Inc.
ISRG
1.46
Intuitive Surgical
JNJ
0.23
Johnson & Johnson
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
PEN
Penumbra, Inc.
ISRG
Intuitive Surgical
JNJ
2.0%
Johnson & Johnson
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
PEN
11.3%
Penumbra, Inc.
ISRG
26.2%
Intuitive Surgical
JNJ
0.8%
Johnson & Johnson

Episode timeline

Episode archive for PEN

Each row is one earnings episode with every verified platform link available.

Q1 2026
Episode live
2026-04-23
Published youtube complete
PEN Stock: EPS Beats by 8% — Q1 2026 Earnings Analysis
Quarterly earnings-analysis entry for Penumbra, Inc.. Use the links on the right to open the video or podcast episode.
Deep Dive
Episode live
2026-04-23
Published podcast complete
Charged Alpha | Penumbra Inc (PEN) | S&P 500 Deep Dive — Ep. 166
Quarterly earnings-analysis entry for Penumbra, Inc.. Use the links on the right to open the video or podcast episode.